Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer

Purpose: DNA damage repair can lead to epigenetic changes. DNA mismatch repair proteins bind to platinum DNA adducts and at sites of DNA damage can recruit the DNA methylating enzyme DNMT1, resulting in aberrant methylation. We hypothesised that DNA damage repair during platinum-based chemotherapy may cause aberrant DNA methylation in normal tissues of patients such as blood. Experimental Design: We used Illumina 450k methylation arrays and bisulphite pyrosequencing to investigate methylation at presentation and relapse in blood DNA from patients with ovarian cancer enrolled in the SCOTROC1 trial (n = 247) and in a cohort of ovarian tumor DNA samples collected at first relapse (n = 46). We used an ovarian cancer cell line model to investigate the role of the DNA mismatch repair gene MLH1 in platinum-induced methylation changes. Results: Specific CpG methylation changes in blood at relapse are observed following platinum-based chemotherapy and are associated with patient survival, independent of other clinical factors [hazard ratio, 3.7; 95% confidence interval, 1.8–7.6, P = 2.8 × 10−4]. Similar changes occur in ovarian tumors at relapse, also associated with patient survival (hazard ratio, 2.6; 95% confidence interval, 1.0–6.8, P = 0.048). Using an ovarian cancer cell line model, we demonstrate that functional mismatch repair increases the frequency of platinum-induced methylation. Conclusions: DNA methylation in blood at relapse following chemotherapy, and not at presentation, is informative regarding survival of patients with ovarian cancer. Functional DNA mismatch repair increases the frequency of DNA methylation changes induced by platinum. DNA methylation in blood following chemotherapy could provide a noninvasive means of monitoring patients' epigenetic responses to treatment without requiring a tumor biopsy. Clin Cancer Res; 23(9); 2213–22. ©2016 AACR.

[1]  Robert Brown,et al.  Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment? , 2017, Current cancer drug targets.

[2]  S. Baylin,et al.  Mismatch repair proteins recruit DNA methyltransferase 1 to sites of oxidative DNA damage. , 2016, Journal of molecular cell biology.

[3]  Robert Brown,et al.  Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer , 2016, Clinical Cancer Research.

[4]  E. Berns,et al.  Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. , 2016, European journal of cancer.

[5]  P. Vineis,et al.  Hypomethylation of smoking-related genes is associated with future lung cancer in four prospective cohorts , 2015, Nature Communications.

[6]  M. Beckmann,et al.  Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses , 2016 .

[7]  Robert Brown,et al.  Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues , 2015, BMC Cancer.

[8]  A. Ashworth,et al.  Temporal Stability and Determinants of White Blood Cell DNA Methylation in the Breakthrough Generations Study , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[9]  N. Zaffaroni,et al.  Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells. , 2014, Cancer letters.

[10]  Rafael A. Irizarry,et al.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..

[11]  K. Hansen,et al.  Functional normalization of 450k methylation array data improves replication in large cancer studies , 2014, Genome Biology.

[12]  Peter A. Jones,et al.  Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers , 2014, Oncotarget.

[13]  Sebastian M. Armasu,et al.  Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome , 2014, BMC Medical Genomics.

[14]  R. Brown,et al.  Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Paolo Vineis,et al.  Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. , 2013, Human molecular genetics.

[16]  R. Weksberg,et al.  Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray , 2013, Epigenetics.

[17]  Devin C. Koestler,et al.  DNA methylation arrays as surrogate measures of cell mixture distribution , 2012, BMC Bioinformatics.

[18]  S. Baylin,et al.  Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. , 2011, Cancer cell.

[19]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[20]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[21]  J. W. Kim,et al.  Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. , 2006, Oncology research.

[22]  S. Baylin,et al.  Double Strand Breaks Can Initiate Gene Silencing and SIRT1-Dependent Onset of DNA Methylation in an Exogenous Promoter CpG Island , 2008, PLoS genetics.

[23]  A. Porcellini,et al.  DNA Damage, Homology-Directed Repair, and DNA Methylation , 2007, PLoS genetics.

[24]  V. O’Brien,et al.  Signalling cell cycle arrest and cell death through the MMR System. , 2006, Carcinogenesis.

[25]  Alan Gordon,et al.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.

[26]  G. Hirst,et al.  Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes , 1999, Current Biology.

[27]  R. Baan,et al.  Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. , 1995, Biochemistry.